Issue link: http://osercommunicationsgroup.uberflip.com/i/562595
C h a i n D r u g s t o r e D a i l y Tu e s d a y, A u g u s t 2 5 , 2 0 1 5 8 4 creams and ointments. With in-depth industry experience, its management team has begun leading the TAGI Pharma emergence, focusing on sales and marketing, product acquisition and product development activities. With an established presence in the U.S. market, led by the drive of its manage- ment team and accomplished by the dedication and efforts of intercompany synergy, TAGI will continue its soar to new heights. Differentiators TAGI's strength is derived from an understanding of the market and identifi- cation of product opportunities. Its mar- keting mix utilizes various platforms compounded into the TAGI formulation. Its product quality and high service levels drive performance. Its current and still expanding product portfolio consists of nine product families with 18 SKUs. Its portfolio is built through licensing, acquisition and development initiatives. A full pipeline keeps a constant flow of new product launches. TAGI Pharma (Cont'd. from p. 1) Product Portfolio Alendronate Sodium Oral Solution 70mg/75mL: Only oral solution/generic alternative to tablets. Astringent Solution Powder Packets: Generic to Bayer's Domeboro ® with con- sumer coupons (GCN# 31828). Benzoyl Peroxide Emollient Foam: three SKUs with consumer coupons (GCN# 27596 and 29303). Nivatopic Plus Cream: 2014 launch with consumer coupons (GCN# 30324). Flavoxate Hydrochloride 100mg Tablets, Hydromorphone Hydrochloride 8mg Tablets, USP (CII), Naltrexone Hydrochloride 50mg Tablets, USP, Phentermine Hydrochloride 37.5mg Tablets, USP (CIV), and Phentermine Hydrochloride 15mg and 30mg Capsules, USP (CIV). Visit TAGI Pharma at booth #1204. Go online to www.tagipharma.com to view complete product listings and full pre- scribing information which includes indi- cations for use and additional important safety information. pharmacist. Pharmacists are some of the most accessible and trusted healthcare providers in the U.S., and they can have a direct impact on patients' behavior. Studies have shown that direct pharma- cist interaction is key to helping patients take their medication correctly, and that the length of therapy directly influences patients' clinical outcomes. The key to driving adherence is to create and capitalize on the personal rela- tionship between patient and pharmacist, and key to that is communicating with patients according to their preferences. RxTouch SM , a suite of patient com- munication solutions from MarkeTouch Media, allows pharmacies to use patient preferences to customize a communica- tion strategy and manage it at the store, call center or corporate level. For exam- ple, Optimum MedSync, a service that aligns prescription refills to a common date, offers multimodal communication channels – automated and live calls, SMS/texts, emails and push notifica- tions. By allowing patients to choose their channel preferences and applying industry best practices, MarkeTouch Media's solution means higher patient opt-in rates for their clients. The RxTouch service line also includes Outbound Notifications, Pharmacist Connect, Central IVR, Mobile/Web Solutions, Health & Wellness Scheduler, Clinical Solutions and Data Analytics. MarkeTouch Media (Cont'd. from p. 1) Research-Based Interventions MarkeTouch Media's Data Analytics solution drives adherence by targeting interventions at patients who are most likely to change their behavior. By ana- lyzing a chain's total dataset, this solu- tion identifies and segments payors or drugs that do not meet the client's goals. Acting on the results can have significant impact on the overall metrics of a phar- macy chain, including increasing a chain's bottom line, improving patient outcomes and lowering overall health- care costs. Post-Hospital Care Coordination MarkeTouch Media's Care Coordination Suite leverages its phar- macy network of more than 14,000 locations to provide patients dis- charged from the hospital with seam- less transitions to their local communi- ty pharmacies. This coordination cre- ates incentives for hospitals under Medicare rules and contributes to a higher level of patient care for those patients most at risk for hospital read- missions. MarkeTouch Media technol- ogy enables connectivity and efficient communication among hospitals, doc- tors and pharmacies to provide timely and accurate patient care – the kind of innovation necessary to meet CMS technical requirements for providing quality patient care. Visit MarkeTouch Media at booth #1414 or online at www.rxtouch.com. strong ability to master and manage com- plexity. Our first two years as an inde- pendent company have been remarkable by all accounts. At the time of spin, our business was split equally in terms of rev- enues between Specialty Pharmaceuticals and Global Medical Imaging. Our goal was to create a diversified, global, spe- cialty biopharmaceutical company that is focused on both generic and branded products, with an emphasis on drugs that are highly durable. Since then we have made three acquisitions, driven signifi- cant growth and substantially increased shareholder value. CDD: Tell our readers about those three key acquisitions. MT: In March 2014, Mallinckrodt acquired what is now its Hospital Therapies – Acute Care business, and in April 2014 we announced a transforma- tive acquisition, which established our Autoimmune and Rare Diseases platform, which we closed on in August 2014. In April 2015, we acquired what is now our Hospital Therapies – Critical Care busi- ness. These are examples of moves that – coupled with steady business perform- ance from our Specialty Generics busi- ness – are enabling us to achieve our goals to drive growth and performance in line with top-quartile peer companies. CDD: What are the company's plans for the Specialty Generics segment? MT: Our Specialty Generics segment remains an important platform for the company. Mallinckrodt has decades of expertise in this area and enjoys one of the broadest, most diverse specialty generic portfolios in the industry, with more than 40 different products and a significant market share in controlled Mallinckrodt (Cont'd. from p. 1) substances. We continually demonstrate our commitment to leadership through our ability to promise customers a reli- able source of supply, ensure quality and stay competitive in the marketplace. We also are continually investing in the busi- ness to maintain the infrastructure, port- folio strength and breadth that allow us to respond effectively to market dynamics. CDD: Explain the company's mission statement – "Managing Complexity. Improving Lives." MT: Put simply, we believe our mission statement gets to the heart of who we are and what we do. We are exceptionally adept at managing complexity, including regulatory expertise and the handling of highly regulated and complex controlled substances; the products we develop, manufacture, sell and distribute are impor- tant to patients' lives. Where others see complexity, we believe Mallinckrodt sees opportunity to provide value to patients and shareholders, and to improve lives. CDD: What sets Mallinckrodt apart? MT: We believe that our ability to solve complex medical challenges takes a unique combination of skills and strengths. Our core capabilities enable us to turn complexity into solutions for patients. These capabilities include prod- uct development and reformulation, reg- ulatory expertise, skilled handling of highly regulated and complex materials, and manufacturing and logistics. Our ability to manufacture complex products and deliver them efficiently to our cus- tomers and the patients they serve reflects our values of quality, integrity and service. Visit Mallinckrodt at booth #115. For more information, call 800.325.8888 or go to www.mallinckrodt.com. logistics, and LED lighting and displays. It's a process that enables companies to derive more value from a variety of under- performing or excess assets. It could be any asset on your balance sheet, such as inven- tory, capital equipment, real estate, vacant land or even marketing sponsorships, that has suffered a diminution in value. In return for receiving more value for that asset, companies commit to buy services through the corporate trade company. CDD: How does corporate trade work? KF: The way it works is that we pur- chase a client's assets using cash, trade credits or a combination of the two. We generally pay a multiple of the fair mar- ket value in trade credits. So instead of receiving 30 cents on the dollar like you might through liquidation of that asset, we can help you restore value to a much higher level using our trading method- ology. Our clients then monetize the value they received by buying goods and services through Active, where we've created leverage through our trading process. In effect, they've used their excess asset to partially offset the cost of an expense. CDD: Who should use corporate trade and when? KF: The majority of our clients are con- sumer facing brands. As a general rule of thumb, companies looking for a corpo- rate trade partner should ensure that the partner can provide services that are in line with their expenditure areas. There Active International (Cont'd. from p. 1) are also a number of different scenarios in which corporate trade adds value. It really depends on the business. Your pri- ority might be to generate cash flow sav- ings, restore lost value to assets, improve bottom line performance or drive a sav- ings around a specific initiative. There's enough flexibility in the trading model to meet whatever it is that you're trying to achieve. The process for structuring the trade is typ- ically the same for each client. We're going to take a look at the assets that have suffered a diminution of value and develop a mutual understanding around where and how those assets can be sold. At the same time, we're going to conduct due diligence around what it is that you're planning to spend through the corporate trade model to ensure that trading component will drive the additional value for you. At the end of the day, it really is about what your immediate needs and long- term plans are and how we can struc- ture a transaction to meet those objec- tives and goals. CDD: What's the easiest way to learn more about corporate trade and how companies can use it effectively? KF: Come see us at our booth and we'll talk about how we can help you address a current business challenge. We'll also give you a power bank so you can stay fully charged (while supplies last). Visit Active International at booth #3131. For more information, go to www.activeinternational.com/NACDS20 15 or call 845.735.1700.